Quadrature Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Quadrature Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.12M	Sell	44,978 -438,554	-91%	-$59.3M	0.06%	226
2026 Q1	$61.8M	Buy	+483,532	New	+$60.4M	0.73%	28
2025 Q4	–	Sell	-45,501	Closed	-$4.56M	–	1706
2025 Q3	$4.56M	Buy	+45,501	New	+$4.1M	0.05%	208
2024 Q2	–	Sell	-89,384	Closed	-$8.48M	–	1580
2024 Q1	$8.48M	Buy	+89,384	New	+$8.29M	0.15%	122

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Quadrature Capital's XBI Position: Q2 2026 in Review

Quadrature Capital reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 91% in Q2 2026, selling an estimated $59.3M and leaving 44,978 shares worth $7.12M. The position accounts for 0.06% of the portfolio, ranked #226.

Quadrature Capital first reported a position in XBI in Q1 2024 and has held it in 4 quarters since. The position peaked at $61.8M in Q1 2026. 936 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Quadrature Capital held 44,978 shares of State Street SPDR S&P Biotech ETF worth $7.12M as of Q2 2026.
Quadrature Capital sold 438,554 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $59.3M.
State Street SPDR S&P Biotech ETF made up 0.06% of Quadrature Capital's portfolio in Q2 2026, its #226 holding.
Quadrature Capital first reported a position in State Street SPDR S&P Biotech ETF in Q1 2024 and has held it in 4 quarters since.
Quadrature Capital's State Street SPDR S&P Biotech ETF position peaked at $61.8M in Q1 2026.
936 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.